Effect of Treprostinil on the Early Postoperative Prognosis of Patients with Severe Left Heart Valvular Disease Combined with Severe Pulmonary Hypertension

Overview

Journal Ann Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2020 Jun 5

PMID 32493870

Citations 3

Authors

Shu-Ting Huang

Ning Xu

Kai-Peng Sun

Qiang Chen

Hua Cao

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect of treprostinil on the early postoperative prognosis of patients with severe left heart valvular disease combined with severe pulmonary hypertension (PAH).

Methods: A retrospective study including 55 patients with severe left heart valvular disease combined with severe PAH who underwent left heart valve replacement in our hospital between January 2019 and May 2019 was conducted. Patients were divided into two groups (treprostinil group and control group), and the clinical data of patients in the two groups were compared and analyzed.

Results: Compared with the preoperative status, the mean postoperative pulmonary artery pressure (mPAP) in both groups was significantly lower. Compared with the control group, the treprostinil group had a significantly lower mPAP. Moreover, the postoperative mechanical ventilation time, intensive care unit (ICU) stay, and hospital stay of the treprostinil group were significantly shorter than those of the control group. There were no serious drug-related side effects in either group.

Conclusions: Treprostinil can improve the early postoperative prognosis of patients with severe left heart valvular disease combined with severe PAH undergoing prosthetic valve replacement.

Citing Articles

Hepatic ischemia-reperfusion syndrome and its effect on the cardiovascular system: The role of treprostinil, a synthetic prostacyclin analog.

Mouratidou C, Pavlidis E, Katsanos G, Kotoulas S, Mouloudi E, Tsoulfas G World J Gastrointest Surg. 2023; 15(9):1858-1870.

PMID: 37901735 PMC: 10600776. DOI: 10.4240/wjgs.v15.i9.1858.

Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial.

Chen X, Cai X, Zhang M, Xu J, Li H, Xu Z Ann Transl Med. 2021; 9(14):1163.

PMID: 34430604 PMC: 8350654. DOI: 10.21037/atm-21-3188.

Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.

Xu N, Huang S, Sun K, Wang Z, Cao H, Chen Q BMC Cardiovasc Disord. 2020; 20(1):472.

PMID: 33143649 PMC: 7641841. DOI: 10.1186/s12872-020-01759-9.

References

Richter M, Ewert R, Warnke C, Gall H, Classen S, Grimminger F . Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Clin Res Cardiol. 2016; 106(3):174-182. DOI: 10.1007/s00392-016-1037-2. View

Yang B, Debenedictus C, Watt T, Farley S, Salita A, Hornsby W . The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis. J Thorac Cardiovasc Surg. 2016; 152(2):394-400.e1. DOI: 10.1016/j.jtcvs.2016.02.038. View

El-Kersh K, Ruf K, Smith J . Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable. Am J Ther. 2016; 25(2):e213-e217. DOI: 10.1097/MJT.0000000000000443. View

Benza R, Tapson V, Gomberg-Maitland M, Poms A, Barst R, McLaughlin V . One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant. 2013; 32(9):889-96. DOI: 10.1016/j.healun.2013.06.008. View

Lim G . Valvular disease: Prognostic relevance of pulmonary hypertension in valvular disease. Nat Rev Cardiol. 2015; 12(4):194. DOI: 10.1038/nrcardio.2015.29. View

Jing Z, Parikh K, Pulido T, Jerjes-Sanchez C, White R, Allen R . Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127(5):624-33. DOI: 10.1161/CIRCULATIONAHA.112.124388. View

Keogh A, Jabbour A, Weintraub R, Brown K, Hayward C, Macdonald P . Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2007; 26(11):1079-83. DOI: 10.1016/j.healun.2007.07.040. View

Hu P, Liu X, Liang J, Zhu Q, Pu C, Tang M . A hospital-based survey of patients with severe valvular heart disease in China. Int J Cardiol. 2016; 231:244-247. DOI: 10.1016/j.ijcard.2016.11.301. View

Tichelbacker T, Dumitrescu D, Gerhardt F, Stern D, Wissmuller M, Adam M . Pulmonary hypertension and valvular heart disease. Herz. 2019; 44(6):491-501. DOI: 10.1007/s00059-019-4823-6. View

10.

LeVarge B, Channick R . Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 2012; 6(3):255-65. DOI: 10.1586/ers.12.23. View

11.

Rubenfire M, McLaughlin V, Allen R, Elliott G, Park M, Wade M . Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007; 132(3):757-63. DOI: 10.1378/chest.06-2118. View

12.

Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A . A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. Clin Pharmacokinet. 2016; 55(12):1495-1505. PMC: 5107196. DOI: 10.1007/s40262-016-0409-0. View

13.

Kabbach G, Mukherjee D . Pulmonary Hypertension secondary to Left Heart Disease. Curr Vasc Pharmacol. 2017; 16(6):555-560. DOI: 10.2174/1570161115666170913105424. View

14.

Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P . The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med. 2017; 11(6):491-503. DOI: 10.1080/17476348.2017.1317599. View

15.

Torres F, Rubin L . Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2012; 11(1):13-25. DOI: 10.1586/erc.12.160. View

16.

Wang T, Lu J, Li Q, Chen Y, Ye Q, Gao J . Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study. Anesth Analg. 2019; 129(6):1607-1612. DOI: 10.1213/ANE.0000000000003827. View

17.

Iung B, Vahanian A . Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011; 8(3):162-72. DOI: 10.1038/nrcardio.2010.202. View

18.

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

19.

Song X, Zhang C, Chen X, Chen Y, Shi Q, Niu Y . An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease. J Cardiothorac Surg. 2015; 10:70. PMC: 4431035. DOI: 10.1186/s13019-015-0274-1. View

20.

Lambers C, Kornauth C, Oberndorfer F, Boehm P, Tamm M, Klepetko W . Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. PLoS One. 2018; 13(11):e0205195. PMC: 6211661. DOI: 10.1371/journal.pone.0205195. View